Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode?

Monica McNeil

2017-11-24 08:41:00 Fri ET

Is Bitcoin a legitimate (crypto)currency or a new bubble waiting to implode? As its prices skyrocket, bankers, pundits, and investors increasingly take sides. In accordance with Warren Buffett's intrinsic value philosophy, Bitcoin should not be viewed as a valuable asset because Bitcoin cannot yield future cash flows. Further, several bankers and experts such as Brian Moynihan (Bank of America CEO), Jamie Dimon (JPMorgan Chase CEO), Bill Dudley (New York Fed CEO), and Joseph Stiglitz (Nobel Laureate) emphasize that Bitcoin cannot be a stable store of value in light of its volatile price movements and technical impediments for Bitcoin to be a long-term viable legal tender. Nobel Laureate Robert Shiller regards Bitcoin as the modern epitome of a speculative asset bubble.

In contrast to this rather pessimistic view, many other proponents suggest that Bitcoin can serve as an alternative virtual currency in addition to legal tender in the current global payments system (especially for many emerging economies with weak legal rules, institutions, and unstable currencies). These proponents include Christine Lagarde (IMF Executive Director), Mark Cuban (VC billionaire), Peter Thiel (PayPal co-founder and VC billionaire), Bill Gates (Microsoft founder and philanthropist), Eric Schmidt (Alphabet chairman), Richard Branson (Virgin Group founder), Mark Carney (Governor of Bank of England), and so forth.

Time will tell whether Bitcoin will become a successful cryptocurrency!!

 


If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.

Blog+More

Allianz chairman Mohamed El-Erian bolsters a new American economic paradigm in lieu of the Washington consensus.

Apple Boston

2018-04-20 10:38:00 Friday ET

Allianz chairman Mohamed El-Erian bolsters a new American economic paradigm in lieu of the Washington consensus.

Allianz chairman Mohamed El-Erian bolsters a new American economic paradigm in lieu of the Washington consensus. The latter dominates the old school of thou

+See More

Conor McGregor learns a major money lesson from LeBron James.

Daisy Harvey

2019-08-07 12:33:00 Wednesday ET

Conor McGregor learns a major money lesson from LeBron James.

Conor McGregor learns a major money lesson from LeBron James. This lesson suggests that James spends about $1.5 million on his own body each year. The $1.5

+See More

The financial services industry needs fewer banks worldwide.

Daphne Basel

2022-08-30 10:32:00 Tuesday ET

The financial services industry needs fewer banks worldwide.

The financial services industry needs fewer banks worldwide. As long as banks have existed in human history, their managers have realized how not all dep

+See More

Treasury bond yield curve inversion often signals the next economic recession in America.

Monica McNeil

2018-10-11 08:44:00 Thursday ET

Treasury bond yield curve inversion often signals the next economic recession in America.

Treasury bond yield curve inversion often signals the next economic recession in America. In fact, U.S. bond yield curve inversion correctly predicts the da

+See More

AYA free finbuzz podcast channel on YouTube March 2019

Andy Yeh Alpha

2019-03-31 11:40:00 Sunday ET

AYA free finbuzz podcast channel on YouTube March 2019

AYA Analytica free finbuzz podcast channel on YouTube March 2019 In this podcast, we discuss several topical issues as of March 2019: (1) Sargent-Wallac

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More